Taiwan Biomaterial Company

# Investor Conference Third Quarter 2025

2025/11/18

# TWBM

- Product: Foamagen Dura substitute, Stroke aspiration systems, and other interventional medical devices and accessories
- Established : November 12, 2012
- Location: Hsinchu Biomedical Science Park
- Capital: NT$420 million
- Chairman: Simon Tsung
- President: Derek Ma
- Employees: 62 people


TWBM

# Milestones

6649

2012 – Company Founded

2016 – Investment by Netronix

2017-Entered the Emerging Stock Market

2019 – OTC Listed; Aspiration Pump exported to U.S.


2020-Foamagen clinically adopted in Taiwan

2022 – Relocated to new building



# Products in Neurosurgery & Vascular Procedures

- **Neurosurgery-Foamagen**


- **Thrombectomy-Neuro/Peripheral vascular aspiration saystem**



TWBM

# Foamagen


- Fits securely and safely
- Dura repair & reduced cerebrospinal fluid leakage



TWBM

# Foamagen

- 300+ cases in Taiwan
- Data presented in teaching hospital conferences
- Planning international journal submissions
- East Asia market expansion underway

TWBM

# Stroke Aspiration System

- **Stroke Type**
  - **Ischemic**

    **70%~80%**
  - **Hemorrhagic**

    20%~30%



TWBM

# Stroke Aspiration System

## ➢ Ischemic Stroke (Cerebral Infarction) Treatment Approaches

- Intravenous thrombolytic drugs (TPA)
  - administered within 4 hours after stroke onset; requires long-term antiplatelet medication afterward

- **Thrombectomy**
  - **performed within 4–24 hours after onset — “one-time definitive treatment.”**

TWBM

# Stroke Aspiration System

1

Neurovascular guidewire(Unique, Next rising star) :
Product  launch in 2026/Q1
Manufacture capacity expansion



2

Gen 2 Canister: Driving overall growth in accessories sales volume

TWBM

Taiwan Biomaterial Company

# Operating Results
# 2025 Q3

# Revenue Trend




TWBM

# Revenue -Quarter




TWBM

# Gross Profit & Margin

Unit: NT T ; %



# Gross Profit & Margin-Quarter

Unit: NT T ; %



# Operating Expenses

Unit: NT T




TWBM

# Operating Expenses (Quarter)

Unit: NT T




TWBM

# Operating Income(Loss)

Unit: NT T



# Operating Income(Loss) (Quarter)



# EPS

Unit: NT $



# EPS- (Quarter)

Unit: NT $



# Other Key Financial Information

Unit: NT T

| | 2025/9/30 | | 2024/9/30 | | Change | YoY% |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 256,001 | 33% | 192,271 | 28% | 63,730 | 33% |
| Financial assets measured at amortized cost | 107,500 | 14% | 107,500 | 15% | - | 0% |
| Accounts receivable | 23,747 | 3% | 8,216 | 1% | 15,531 | 189% |
| Inventory | 35,105 | 5% | 44,862 | 6% | (9,757) | -22% |
| Current assets | 23,347 | 3% | 8,942 | 1% | 14,405 | 161% |
| Property, plant and equipmen | 263,577 | 34% | 273,334 | 39% | (9,757) | -4% |
| Right of use assets | 51,350 | 7% | 55,914 | 8% | (4,564) | -8% |
| Non-current assets | 6,509 | 1% | 6,652 | 1% | (143) | -2% |
| Total assets | 767,136 | 100% | 697,691 | 100% | 69,445 | 10% |
| Current liabilities | 36,555 | 5% | 19,541 | 3% | 17,014 | 87% |
| Non-current liabilities | 49,249 | 6% | 53,697 | 8% | (4,448) | -8% |
| Total liabilities | 85,804 | 11% | 73,238 | 10% | 12,566 | 17% |
| Total equity | 681,332 | 89% | 624,453 | 90% | 56,879 | 9% |


TWBM